GSK plc (LON:GSK) Stock Has Consensus Price Target of GBX 2,064.38

Key Points

• Analysts have a consensus “Hold” rating on GSK, with five holds, two buys and one sell. The average 12-month price target is GBX 2,064.38, above the reported opening price of GBX 1,894.
• Recent broker targets range from GBX 1,975 to GBX 2,500, including Jefferies’ “buy” rating and GBX 2,500 target, while Berenberg raised its target to GBX 2,200 but maintained a hold rating.
• GSK reported quarterly EPS of GBX 10.80, with a 14.52% net margin and 28.35% return on equity. Insiders also purchased shares recently, although insider ownership remains low at 0.20%.

GSK plc (LON:GSK - Get Free Report) has earned an average recommendation of "Hold" from the eight brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is GBX 2,064.38.

A number of analysts have commented on the stock. Berenberg Bank upped their price objective on shares of GSK from GBX 2,000 to GBX 2,200 and gave the company a "hold" rating in a research note on Tuesday, September 15th. Royal Bank Of Canada reissued a "sector perform" rating and set a GBX 1,975 target price on shares of GSK in a research note on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a GBX 2,000 target price on shares of GSK in a research note on Tuesday, September 29th. Finally, Jefferies Financial Group restated a "buy" rating and issued a GBX 2,500 target price on shares of GSK in a report on Tuesday, October 20th.

Insider Activity

In other GSK news, insider Anne Beal bought 637 shares of the stock in a transaction on Friday, September 18th. The shares were purchased at an average cost of GBX 4,985 per share, with a total value of £31,754.45. Also, insider Jonathan Symonds purchased 1,500 shares of the stock in a transaction on Friday, September 18th. The shares were bought at an average price of GBX 1,881 per share, for a total transaction of £28,215. Over the last ninety days, insiders acquired 2,151 shares of company stock worth $6,021,921. Insiders own 0.20% of the company's stock.

GSK Price Performance

Shares of GSK stock opened at GBX 1,894 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 103.36. The company's 50-day moving average price is GBX 1,847.39 and its two-hundred day moving average price is GBX 1,918.60. GSK has a 52 week low of GBX 1,592 and a 52 week high of GBX 2,282. The stock has a market cap of £75.89 billion, a PE ratio of 16.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.29.

GSK (LON:GSK - Get Free Report) last released its earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. As a group, sell-side analysts anticipate that GSK will post 175.98 EPS for the current fiscal year.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.